Brokerages forecast that Atara Biotherapeutics (NASDAQ:ATRA) will announce earnings of ($0.93) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($0.97) and the highest estimate coming in at ($0.85). Atara Biotherapeutics reported earnings per share of ($0.88) in the same quarter last year, which suggests a negative year over year growth rate of 5.7%. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($3.58) per share for the current financial year, with EPS estimates ranging from ($3.75) to ($3.49). For the next year, analysts forecast that the firm will post earnings of ($3.78) per share, with EPS estimates ranging from ($4.27) to ($3.41). Zacks’ EPS averages are an average based on a survey of research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.15).
A number of equities research analysts have issued reports on the stock. JPMorgan Chase assumed coverage on shares of Atara Biotherapeutics in a research note on Tuesday. They set an “overweight” rating and a $56.00 target price for the company. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research note on Wednesday, January 3rd. Canaccord Genuity reaffirmed a “positive” rating and issued a $70.00 price objective (up previously from $47.00) on shares of Atara Biotherapeutics in a research note on Friday, January 19th. William Blair reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, April 6th. Finally, BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $37.50.
Shares of NASDAQ:ATRA traded down $1.60 during trading on Friday, reaching $40.60. 642,566 shares of the company traded hands, compared to its average volume of 1,013,198. The firm has a market capitalization of $1,605.45, a P/E ratio of -10.15 and a beta of 2.55. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $49.90.
In related news, Director Carol Giltner Gallagher sold 1,183 shares of Atara Biotherapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $46.50, for a total value of $55,009.50. Following the transaction, the director now owns 111,286 shares in the company, valued at approximately $5,174,799. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 48,500 shares of Atara Biotherapeutics stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $34.58, for a total transaction of $1,677,130.00. Following the completion of the transaction, the chief executive officer now owns 348,978 shares in the company, valued at approximately $12,067,659.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 245,424 shares of company stock valued at $9,872,689. 16.20% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC raised its holdings in Atara Biotherapeutics by 13.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 3,146,820 shares of the biotechnology company’s stock worth $56,957,000 after acquiring an additional 371,099 shares during the period. Bridger Management LLC raised its holdings in Atara Biotherapeutics by 57.3% in the 4th quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock worth $47,035,000 after acquiring an additional 946,086 shares during the period. Carillon Tower Advisers Inc. bought a new position in Atara Biotherapeutics in the 4th quarter worth $23,284,000. Neuberger Berman Group LLC raised its holdings in Atara Biotherapeutics by 15.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after acquiring an additional 147,061 shares during the period. Finally, Artal Group S.A. raised its holdings in Atara Biotherapeutics by 66.7% in the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after acquiring an additional 400,000 shares during the period. Hedge funds and other institutional investors own 76.88% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/20/zacks-analysts-anticipate-atara-biotherapeutics-atra-will-post-earnings-of-0-93-per-share.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.